Yizhak Kupfer, MD; Tatsuji Namba, MD, PhD; Emad Kaldawi, MD; Sidney Tessler, MD
Vecuronium bromide is a nondepolarizing neuromuscular blocking agent chemically similar to pancuronium, but with minimal cardiovascular side effects (1). Unlike other neuromuscular blocking agents, vecuronium does not cause significant histamine release, which can lead to bronchoconstriction in patients with asthma. Because of its short duration of action, vecuronium can be administered by continuous intravenous infusion. In patients without renal impairment, large doses do not result in accumulation. Thus, vecuronium appears to be an ideal agent to achieve muscle relaxation for patients with respiratory failure, especially status asthmaticus.
In recent years, reports have linked prolonged use of neuromuscular blocking agents to
Learn more about subscription options.
Register Now for a free account.
Kupfer Y, Namba T, Kaldawi E, Tessler S. Prolonged Weakness after Long-Term Infusion of Vecuronium Bromide. Ann Intern Med. 1992;117:484–486. doi: 10.7326/0003-4819-117-6-484
Download citation file:
Published: Ann Intern Med. 1992;117(6):484-486.
Results provided by:
Copyright © 2017 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use
This PDF is available to Subscribers Only